Graph AI, a startup developing AI software for pharmaceutical patient safety operations, has raised $13.3 million in a Series A funding round led by Insight Partners.
/indianstartupnews/media/media_files/2026/06/17/desktop-728-x-90-1-2026-06-17-17-20-35.png)
Existing investor Bessemer Venture Partners also took part in the financing, which Graph AI said will support its expansion across the US and Europe.
The latest investment follows a $3 million seed round led by Bessemer in October 2025.
Founded in 2024, Graph AI develops Graph Safety, a platform intended to automate parts of pharmacovigilance, the monitoring and management of potential safety problems associated with medicines.
The startup said pharmaceutical safety teams still spend significant amounts of time on manual processing and operational tasks.
Graph Safety combines AI with predetermined controls, validation layers and end-to-end audit trails, with the aim of allowing source data and system outputs to be traced and reviewed by people.
The startup claims that in live deployments its software had reduced the time taken to process safety cases from more than three hours to less than 10 minutes, while cutting operating costs by as much as 66%.
Raghav Parvataraju, CEO of Graph AI, said pharmacovigilance had traditionally dealt with growing case volumes by adding staff and processes around older systems.
“We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center. We are not replacing human judgment, we are building technology that allows experts to apply it where it matters most,” he said.
Graph AI has brought two modules to market since its seed round.
Its Intake module is designed to capture and triage incoming reports of adverse events across different channels, while Nucleus is a safety database that automates case processing.
A third module, Report, which is designed to automate aggregate safety reporting, is due to launch in September.
The startup is also working on Signal, a planned module intended to identify emerging safety signals and patterns across cases.
It had onboarded pharmaceutical and biotechnology customers in North America and other markets, and had secured design partnerships for modules still under development.
Richard Matus, principal at Insight Partners, said pharmaceutical companies needed to manage patient safety accurately but generally did not want to integrate a range of separate systems themselves.
“We believe that’s a perfect problem for an AI team that lives inside this industry with complete focus,” he said.
“Patient safety should run an intelligent, integrated platform, not fragmented tools and manual handoffs,” he said.
Graph AI said Graph Safety had been designed with reference to applicable regulatory requirements and changing expectations around the use of AI in medicines development and patient safety.
The startup cited the US Food and Drug Administration’s framework for assessing the credibility of AI models used to support regulatory decision-making. That framework forms part of draft FDA guidance and contains non-binding recommendations.
It also cited the European Union’s AI Act and a report published by the Council for International Organizations of Medical Sciences’ Working Group XIV on the use of AI in pharmacovigilance.
